Glucosparc is a prescription drug that is used to treat type 2 diabetes in adults where only exercise and diet are not enough to control blood sugar levels. Glucosparc may be used alone or combined with other drugs that lowers blood sugar.

Glucosparc contains metformin, a substance that increases the effect of the body's own insulin, which in turn is needed for the body's cells to be able to get energy from glucose, the sugar that is absorbed from food and circulated via blood vessels to the body's cells. Medicines containing metformin have been approved in Sweden since 1965, but Glucosparc may be the first to provide it in the form of a prolonged release tablet. Prolonged release tablets with metformin have long been available in Europe and globally, but in the Nordics only in Finland.

Prolonged release tablets such as Glucosparc dissolve gradually over a longer period, compared to regular tablets that dissolve and are absorbed rapidly by the body. For some patients, the rapid absorption may lead to adverse events and then a prolonged release tablet may be a better choice.

The product is expected to be launched in EQL Pharma's third financial quarter 2021/22.